Enhanced T-type calcium channel 3.2 activity in sensory neurons contributes to neuropathic-like pain of monosodium iodoacetate-induced knee osteoarthritis

Seung Min Shin, PhD1,2, Yongsong Cai, MD, PhD1,3, Brandon Itson-Zoske, BS1, Chensheng Qiu, MD1,4, Xu Hao, MD, PhD1,4, Hongfei Xiang, MD, PhD1,4, Quinn H Hogan, MD1,2, and Hongwei Yu, MD1,2

Abstract
The monosodium iodoacetate knee osteoarthritis model has been widely used for the evaluation of osteoarthritis pain, but the pathogenesis of associated chronic pain is not fully understood. The T-type calcium channel 3.2 (CaV3.2) is abundantly expressed in the primary sensory neurons, in which it regulates neuronal excitability at both the somata and peripheral terminals and facilitates spontaneous neurotransmitter release at the spinal terminals. In this study, we investigated the involvement of primary sensory neuron-CaV3.2 activation in monosodium iodoacetate osteoarthritis pain. Knee joint osteoarthritis pain was induced by intra-articular injection of monosodium iodoacetate (2 mg) in rats, and sensory behavior was evaluated for 35 days. At that time, knee joint structural histology, primary sensory neuron injury, and inflammatory gliosis in lumbar dorsal root ganglia, and spinal dorsal horn were examined. Primary sensory neuron-T-type calcium channel current by patch-clamp recording and CaV3.2 expression by immunohistochemistry and immunoblots were determined. In a subset of animals, pain relief by CaV3.2 inhibition after delivery of CaV3.2 inhibitor TTA-P2 into sciatic nerve was investigated. Knee injection of monosodium iodoacetate resulted in osteoarthritis histopathology, weight-bearing asymmetry, sensory hypersensitivity of the ipsilateral hindpaw, and inflammatory gliosis in the ipsilateral dorsal root ganglia, sciatic nerve, and spinal dorsal horn. Neuronal injury marker ATF-3 was extensively upregulated in primary sensory neurons, suggesting that neuronal damage was beyond merely knee-innervating primary sensory neurons. T-type current in dissociated primary sensory neurons from lumbar dorsal root ganglia of monosodium iodoacetate rats was significantly increased, and CaV3.2 protein levels in the dorsal root ganglia and spinal dorsal horn ipsilateral to monosodium iodoacetate by immunoblots were significantly increased, compared to controls. Perineural application of TTA-P2 into the ipsilateral sciatic nerve alleviated mechanical hypersensitivity and weight-bearing asymmetry in monosodium iodoacetate osteoarthritis rats. Overall, our findings demonstrate an elevated CaV3.2 expression and enhanced function of primary sensory neuron-T channels in the monosodium iodoacetate osteoarthritis pain. Further study is needed to delineate the importance of dysfunctional primary sensory neuron-CaV3.2 in osteoarthritis pain.

Keywords
Osteoarthritis, dorsal root ganglia, neuropathic pain, T-type calcium channel 3.2, whole-cell patch clamp

Introduction
Osteoarthritis (OA) is the most common cause of disability, largely resulted from chronic pain exacerbated by movement and loading on the joint, which is the
 predominant symptom in most patients with OA and often refractory to analgesia. A commonly used preclinical model for OA consists of intra-articular injection of monosodium iodoacetate (MIA), an irreversible inhibitor of glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), into the animal joint space, which produces a joint pathology with similarities to clinical OA and significant pain-related behavior. Knee injection of MIA is highly efficient in inactivating chondrocyte GAPDH, which results in reduced glycolysis and cell death, followed by histological features typical of OA joint damage. The pathogenesis of chronic pain is complex and includes components of joint degeneration with cartilage loss and aggressive subchondral bone lesions and remodeling, musculoskeletal impairments, neurogenic inflammation, and neuropathic injury.

The rat knee joint is abundantly innervated by primary sensory neurons (PSNs) that have somata located in the dorsal root ganglia (DRG) of lumbar (L) 3 to L5 levels. Sensory neuron terminals have been identified throughout the joint, including the capsule, ligaments, menisci, periosteum, and subchondral bone, and the majority of these joint afferents are nociceptive. Studies have demonstrated that sensitization of nociceptor innervating the joint plays a crucial role in MIA joint pain pathogenesis, and this process is accompanied by DRG-PSN injury, gliosis, and extensive abnormalities in peripheral sensory nervous system (PSNS), especially at the late stage of disease, leading to peripheral and central sensitization with features similar to peripheral nerve injury-induced neuropathic pain. Animal studies have shown that reduction of sensory thresholds develops in the hindlimb ipsilateral, and to some degree contralateral, to the knee injured by MIA, suggesting the presence of both peripheral and central sensitization.

Clinical findings, including referred pain and enhanced temporal summation, additionally support the view that peripheral and central sensitization contributes to chronic OA pain. Thus, injury of the PSNs with neuropathic pain-like sensitization is one of the defined mechanistic correlates of OA-associated pain in both animal models and human disease.

T-type calcium 3.2 channels (CaV3.2), which are abundantly expressed in PSNS and their axons, determine low-threshold mechanoreceptor function, and shape neuronal firing properties, has been demonstrated in modulating chronic peripheral and central sensitization in various chronic pain conditions. CaV3.2 expression has also been detected in osteoblasts, osteocytes, and chondrocytes. Several lines of evidence support involvement of CaV3.2 activation in OA pain pathogenesis. It is reported that mechanotransduction in bone is partially mediated through T-type voltage-gated calcium channels, and CaV3.2 knockout mice display reduced cartilage damage following repetitive knee loading-induced OA. Consistent with this notion, oral small molecular selective CaV3.2 inhibitor produces dose-dependent antinociception in rat MIA-induced knee-joint pain. These studies verified that the aberrant CaV3.2 activation in OA pain plays an important role in pain pathogenesis; however, whether PSN-CaV3.2 activation is involved in the MIA-OA pain remains an open question.

This study was designed to investigate whether PSN-CaV3.2 activation plays a role in MIA-OA pain, focusing on the advanced stage of MIA-OA that often presents neuropathic pain-like pathology. We here present the evidence showing that PSN-T-type channel activity was enhanced and CaV3.2 expression increased at the advanced stage of MIA-OA and that neuronal damages beyond exclusively knee-innervating PSNs, which may contribute to the pathogenesis of MIA-OA neuropathic-like pain.

**Methods and Materials**

**Animals**

Experiments were performed in adult male Sprague Dawley rats (5–6 weeks old; 125–150 g body weight) purchased from Charles River Laboratories (Wilmington, MA). Rats were housed in standard 12-h cycle lighting and were allowed ad libitum access to food and water prior to and throughout the experimental protocol. All animal procedures were reviewed and approved by the Animal Care Committee of the Zablocki VA Medical Center Animal Studies Subcommittee and Medical College of Wisconsin IACUC (Permission number: 3690–03). All efforts were made to minimize suffering and the numbers of animals used. For tissue harvest euthanasia, animals were deeply anesthetized by isoflurane followed by decapitation with a well-maintained guillotine. The numbers of rats used were detailed in the relevant sections or figure legends of the experiments.

**Induction of knee OA**

The MIA model of knee OA was induced in isoflurane-anesthetized animals as previously described. Briefly, after briefly anesthetized with isoflurane (2% v/v) vaporized in oxygen, rats received a single intra-articular cavity injection of 2 mg MIA (Sigma–Aldrich, St. Louis, MO) in 50 µl sterile 1x phosphate-buffered saline (saline) through the infrapatellar ligament of the right knee, assisted by flexed the knee at a 90° angle. Control rats received intra-articular injection of saline (50 µl).

**Behavior tests**

Animals were habituated in individual test compartments for at least 1 h before each testing. Behavior
tests carried out as previously described were performed by personnel blind to the injection.

1. **Weight-bearing (WB) asymmetry**: An Incapacitance tester (Columbus Instruments, Columbus, OH) was used to determine hindpaw weight distribution. Rats were placed in an angled Plexiglas chamber so that each hindpaw rested on a separate force plate. The change in hindpaw weight distribution was automatically calculated by Incapacitance tester (the difference in the amount of weight (g) between the left and right limbs). Essentially, the apparatus calculates an average weight distribution over the span of 5 s, and three recordings are taken for each rat. All three recordings are then automatically averaged, and a mean score is displayed. The primary dependent measure was % weight on ipsilateral hindpaw and was determined by the formula: Weight bearings (%) = force (g) of right hindpaw/ [force (g) of left hindpaw + force (g) of right hindpaw] × 100. A value of less than 50% indicates a reduction in weight borne on the ipsilateral hindlimb.

2. **Mechanical allodynia**: Static mechanical withdrawal thresholds (von Frey, vF) were assessed by applying the calibrated monofilaments (Patterson Medical, Bolingbrook, IL) to the plantar surface of the hindpaw. Briefly, beginning with the 2.8 g filament, filaments were applied with just enough force to bend the fiber and held for 1 s. If a response was observed, the next smaller filament was applied, and if no response was observed, the next larger was applied, until a reversal occurred, defined as a withdrawal after a previous lack of withdrawal, or vice versa. Following a reversal event, four more stimulations were performed following the same pattern. The forces of the filaments before and after the reversal, and the four filaments applied following the reversal, were used to calculate the 50% withdrawal threshold. Rats not responding to any filament were assigned a score of 25 g.

3. **Mechanical hyperalgesia**: Noxious punctate mechanical stimulation (Pin test) was performed using the point of a 22 g spinal anesthesia needle that was applied to the center of the hindpaw with enough force to indent the skin but not puncture it. Five applications were separated by at least 10 s, which was repeated after 2 min, making a total of 10 touches. For each application, the induced behavior was either a very brisk, simple withdrawal with immediate return of the foot to the cage floor, or a sustained elevation with grooming that included licking and chewing, and possibly shaking, which lasted at least 1 s. This latter behavior was referred to as hyperalgesic behavior, which is specifically associated with place avoidance. Hyperalgesia was quantified by tabulating hyperalgesia responses as a percentage of total touches.

4. **Cooling stimulation (cold)**: Acetone was expelled from a syringe attached to PE220 tubing to make a meniscus that was touched to the plantar surface of the hindpaw, such that the drop spread out on the plantar surface of the paw without contact of the tubing to the skin. Each hindpaw was tested three times in alternating fashion. Any withdrawal was considered a positive response.

5. **Heating plantar test (heat)**: Heat-pain threshold of the hindpaw was determined using a device designed for the purpose of identifying thermal sensitivity (Paw Thermal Stimulator System, University Anesthesia Research & Development Group, San Diego, CA). Rats were placed on a temperature-regulated glass platform heated to 30°C and the hindpaws stimulated with a radiant heat source (50 W halogen bulb) directed through an aperture. The time elapsed from initiation of the stimulus until withdrawal (withdrawal latency) as detected by a series of photocells was measured. Each hind paw was tested four times and the withdrawal latency values averaged.

**Histology and immunohistochemistry (IHC)**

Following behavior testing at the fifth week after MIA injection, animals were terminally anesthetized. Tissues were used at this timepoint since this represents an advanced stage at which all articular structure and behavior changes associated with OA application have become fully developed.

1. **Knee histopathological analysis**: The knee joints from the tibia to the distal metatarsal including the tarsal joint were resected and fixed with 10% neutral-buffered formalin for 48 h at room temperature. The fixed specimens were decalcified in Immucan (ThermoFisher, Waltham, MA) for two weeks and embedded in paraffin. Sections of the tissue specimens were acquired from the paraffin blocks at 5 µm thickness, deparaffinized and rehydrated in the order of xylene and series of absolute to 50% alcohol. The rehydrated sections were stained with hematoxylin and eosin (H&E) for the observation of morphological changes in the articular tissues. Images of knee joint histology were captured using a Keyence BZ-X800 microscope (Keyence Corporation, Itasca, IL).

2. **Immunohistochemistry (IHC)**: DRG and lumbar spinal cord (SC) segments were dissected, post-fixed in 10% buffered formalin, and processed for paraffin embedding and sectioning. IHC double staining was performed to characterize the distribution of target molecules in tissue sections, as previously described. In brief, after deparaffinized and hydrated, sections were treated by heat-induced antigen epitope retrieval in...
was used, which is raised against a rat CaV3.2 peptide, Hoechst, as previously described. For quantification and non-IR neurons with visible nuclei marked by counting the number of ATF3 immunoreactive (IR) percentage of ATF3-positive DRG neurons was determined. Antigen signals were overlaid. Quantification of the percentage of fold change for each section.

Table 1. Primary antibodies and IgG controls used in this study.

| Antibody   | Host                  | Supplier/Cat#/RRIDb | Dilution      |
|------------|-----------------------|----------------------|---------------|
| IB4        | Rabbit polyclonal     | LF/12143             | 1.0 μg/ml     |
| CaV3.2     | Rabbit polyclonal     | Alomone/ACC025/AB2039781 | 1:500 (IHC), 1:1000 (WB) |
| ATF3       | Rabbit polyclonal     | SCB/SC188            | 1:200 (IHC), 1:800 (WB) |
| Iba1       | Rabbit polyclonal     | Wako/019-19741       | 1:1000 (IHC)  |
| GFAP       | Rabbit polyclonal monoclonal | Dako/Z0334          | 1:500 (IHC)   |
| Tubb3      | Mouse monoclonal      | SCB/sc-80016         | 1:400 (IHC), 1:1000 (WB) |
| GAPDH      | Mouse monoclonal      | Sigma/SAB1403850     | 1:2000 (WB)   |
| IgG control | Mouse                 | LF/31903             | 1:100−400     |
| IgG control | Rabbit                | LF/MAS-16384         | 1:100−1000    |

CaV3.2: T-type voltage-gated calcium channel 3.2; IB4: isolectin IB4; ATF3: activated transcriptional factor 3; Iba1: ionized calcium-binding adapter molecule 1; GFAP: glial fibrillary acidic protein; Tubb3: β3-Tubulin; GAPDH: glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase; IgG: immunoglobulin G; IHC: immunohistochemistry; WB: weight bearing.

A well-characterized CaV3.2 antibody was used, which is raised against a rat CaV3.2 peptide, corresponding to amino acid residues 581–595 of rat CaV3.2 intracellular loop between domains D1 and D2 and its specificity to detect the target has been verified by IHC on CaV3.2 knockout tissue. All antibodies were diluted in 1x PBS, containing 0.05% Triton X-100 and 3% bovine serum albumin (BSA). Normal immunoglobulin G (IgG from the same species as the first antibody, Table 1) was replaced for the first antibody as the negative controls. The appropriate fluorophore-conjugated (Alexa 488 or Alexa 594, 1:2000) secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used to reveal immune complexes. The sections were washed three times for 5 min each with PBS containing 0.05% Tween-20 between incubations. To stain nuclei, 1.0 μg/ml Hoechst33342 (Hoechst, ThermoFisher) was added to the secondary antibody mixture. The sections were examined, and images captured using a Nikon TE2000-S fluorescence microscope (El Segundo, CA) with filters suitable for selectively detecting the green and red fluorescence using a QuantiFire digital camera (Optronics, Ontario, NY). For double label colocalization, images from the same section but showing different antigen signals were overlaid. Quantification of the percentage of ATF3-positive DRG neurons was determined by counting the number of ATF3 immunoreactive (IR) and non-IR neurons with visible nuclei marked by Hoechst, as previously described. For quantification of spinal dorsal horn (SDH) CaV3.2 immunostaining, the Image J (ImageJ v.1.46, National Institutes of Health) was used to quantify changes in immunolabeled fluorescent densities as described previously, with some minor modifications. In brief, the sections with symmetrical width of DHs throughout the mediolateral axis were used for measurement, and the upper and lower threshold optical densities were adjusted to encompass and match the immunoreactivity (IR) that appears in red. A standardized rectangle was first positioned over laminae territory throughout the mediolateral axis on the contralateral DH. The area and density of pixels within the threshold value representing IR were calculated and the integrated density was the product of the area and density. The same box was then moved to the corresponding position on the opposite DH and the integrated density of pixels within the same threshold was again calculated. Comparisons of both sides of DHs were made only within the same sections and density values on the ipsilateral side were expressed as a percent of the contralateral side, providing an estimate of fold change for each section.

Immunoblots

DRG and SDH tissues at the fifth week after MIA or saline injection were harvested. The lysates from DRG and SDH tissues were extracted using 1× RIPA buffer (20 mm Tris-HCl pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, with 0.1% Triton X100 and protease inhibitor cocktail). Protein concentration was determined by using the Pierce BCA kit (ThermoFisher). Equivalent protein samples were size separated using 10% or 4%–20% SDS-PAGE gels (Bio-Rad Laboratories, Des Plaines, IL), transferred to Immun-Blot PVDF membranes (Bio-Rad) and blocked for 1 h in 5% skim milk. The blots were cut into two halves along protein size around 70 KDa and subsequently incubated overnight at 4°C with appropriate antibodies. IR proteins were detected by Pierce enhanced chemiluminescence (ThermoFisher) after incubation for 1 h with HRP-conjugated second antibodies (1:5000, 10 mM citrate buffer, pH 6.0. Sections were first immunolabeled with the selected primary antibodies overnight at 4°C (Table 1). A well-characterized CaV3.2 antibody was used, which is raised against a rat CaV3.2 peptide, corresponding to amino acid residues 581–595 of rat CaV3.2 intracellular loop between domains D1 and D2 and its specificity to detect the target has been verified by IHC on CaV3.2 knockout tissue. All antibodies were diluted in 1x PBS, containing 0.05% Triton X-100 and 3% bovine serum albumin (BSA). Normal immunoglobulin G (IgG from the same species as the first antibody, Table 1) was replaced for the first antibody as the negative controls. The appropriate fluorophore-conjugated (Alexa 488 or Alexa 594, 1:2000) secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used to reveal immune complexes. The sections were washed three times for 5 min each with PBS containing 0.05% Tween-20 between incubations. To stain nuclei, 1.0 μg/ml Hoechst33342 (Hoechst, ThermoFisher) was added to the secondary antibody mixture. The sections were examined, and images captured using a Nikon TE2000-S fluorescence microscope (El Segundo, CA) with filters suitable for selectively detecting the green and red fluorescence using a QuantiFire digital camera (Optronics, Ontario, NY). For double label colocalization, images from the same section but showing different antigen signals were overlaid. Quantification of the percentage of ATF3-positive DRG neurons was determined by counting the number of ATF3 immunoreactive (IR) and non-IR neurons with visible nuclei marked by Hoechst, as previously described. For quantification of spinal dorsal horn (SDH) CaV3.2 immunostaining, the Image J (ImageJ v.1.46, National Institutes of Health) was used to quantify changes in immunolabeled fluorescent densities as described previously, with some minor modifications. In brief, the sections with symmetrical width of DHs throughout the mediolateral axis were used for measurement, and the upper and lower threshold optical densities were adjusted to encompass and match the immunoreactivity (IR) that appears in red. A standardized rectangle was first positioned over laminae territory throughout the mediolateral axis on the contralateral DH. The area and density of pixels within the threshold value representing IR were calculated and the integrated density was the product of the area and density. The same box was then moved to the corresponding position on the opposite DH and the integrated density of pixels within the same threshold was again calculated. Comparisons of both sides of DHs were made only within the same sections and density values on the ipsilateral side were expressed as a percent of the contralateral side, providing an estimate of fold change for each section.

Immunoblots

DRG and SDH tissues at the fifth week after MIA or saline injection were harvested. The lysates from DRG and SDH tissues were extracted using 1× RIPA buffer (20 mm Tris-HCl pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, with 0.1% Triton X100 and protease inhibitor cocktail). Protein concentration was determined by using the Pierce BCA kit (ThermoFisher). Equivalent protein samples were size separated using 10% or 4%–20% SDS-PAGE gels (Bio-Rad Laboratories, Des Plaines, IL), transferred to Immun-Blot PVDF membranes (Bio-Rad) and blocked for 1 h in 5% skim milk. The blots were cut into two halves along protein size around 70 KDa and subsequently incubated overnight at 4°C with appropriate antibodies. IR proteins were detected by Pierce enhanced chemiluminescence (ThermoFisher) after incubation for 1 h with HRP-conjugated second antibodies (1:5000,
Bio-Rad). The densitometry of bands of interests was analyzed using ImageJ v.1.46. Ratios of the band density of the target proteins to GAPDH band density were calculated and the percentage changes of target proteins in the experimental samples compared with those from the control samples.37,38

**Whole-cell patch-clamp recording of T-type Ca\(^{2+}\) channel current on dissociated DRG neurons**

Whole-cell patch-clamp recording on dissociated DRG neurons was performed, as described previously.39 In brief, the DRG (L3, L4, and L5) were rapidly harvested from the isoflurane-anesthetized animals and were incubated in 0.01% blendzyme 2 (Roche Diagnostics, Madison, WI) for 30 min followed by incubation in 0.25% trypsin and 0.125% DNase for 30 min, both dissolved in DMEM/F12 with glutaMAX (ThermoFisher). After exposure to 0.1% trypsin inhibitor and centrifugation, the pellet was gently triturated in culture medium containing Neural basal media A (ThermoFisher) plus 0.5 mM nisoldipine, and 0.2 mM mibefradil to blocks N-type ICa, and m\(_0.2\) mM): 135 tetra-methyl ammonium hydroxide (TMAOH), and pH 7.2 with hydrofluoric acid. A selective and reversible voltage activated (HVA) ICa following incubation of the maximum conductance (G\(_{\text{max}}\)). Normalized activation curves were fitted with a Boltzmann equation G/G\(_{\text{max}}\) = 1/(1+exp(V\(_{50}\)-Vm)/k), where G was calculated as follows: G = I/(Vm-E\(_{\text{rev}}\)). The steady-state inactivation curves were fitted with I/Imax = 1/(1+exp(V\(_{50}\)-Vm)/k). In all of the equations, V\(_{50}\) denotes the half-activation and half inactivation potentials, Vm is the membrane potential, E\(_{\text{rev}}\) is the inversion potential, k is the slope factor, G is the conductance, and I is the current at a given Vm; G\(_{\text{max}}\) and I\(_{\text{max}}\) are the maximum conductance and current, respectively.

**Subepineurial sciatic nerve injection**

In this experiment, injection was performed in a blinded manner by which the operator was unaware of the content of the injectate. TTA-P2 was dissolved in dimethyl sulfoxide (DMSO) to a 100 mM stock solution, stored at −20°C, diluted to desired concentrations with saline just before use. It is reported that half of the total cross-section inside the sciatic nerve (SN) epineurium in human consists of non-neural connective tissue.41 Rats at five weeks post MIA knee OA induction were randomized into two groups, and subepineurial sciatic nerve injection (SSNI) was performed as previously described,42,43 with some modification. In brief, after appropriate anesthesia was obtained by inhalation of 2% isoflurane, the SNs were exposed by lateral incision of the middle thighs and division of the superficial fascia and muscle. Then 100 μl of the test dose at TTA-P2

**Shin et al.**
(containing 0.01% DMSO) was injected slowly, directly into subepineural space (beneath the clear fascia surrounding the nerve but outside the perineurium) through a 33-gauge needle, proximal to the sciatic bifurcation. The needle remained in place at the injection site for 1 additional min, before it was slowly removed. The TTA-P2 dose used were saturating in preliminary experiments. Control rats received SSNI with 100 μl saline containing 0.01% DMSO. The superficial muscle layer was sutured with 4–0 silk, and the wound was closed with metal clips. Ipsilateral hindpaw mechanical allodynia (vF) and hyperalgesia (Pin) as well as WB asymmetry were tested before and 15, 30, 45, 60, 120, and 180 min after animal recovered after injection of TTA-P2 or vehicle.

Statistics

All statistical analysis was performed using Prism program (GraphPad Software, San Diego, CA). Data were expressed as means ± SEM. A probability of $p < 0.05$ was considered as statistically significant. Behavioral changes over time in each group were analyzed by repeated measures parametric two-way ANOVA for von Frey, WB, and heat testing with post hoc multiple comparison by Tukey’s test, and non-parametric Friedman’s ANOVA for pin and cold testing with Dunn’s test for post hoc analysis. Differences of ATF3 immunopositivity, patch recording T-channel peak $I_{Ca}$ density, and immunoblot CaV3.2 protein levels between groups were compared with a two-tailed, unpaired $t$ test.

Results

**MIA OA knee histopathology and pain behavior**

Histological examination of H&E staining of knee joints 35 days following intra-articular injections demonstrate that saline-treated knees have intact and smooth articular surfaces. MIA-treated knees displayed typical structural joint damage 35 days after MIA knee cavity injection as reported, showing a considerable loss of articular cartilage surrounding the subchondral bone along the joint, combined with bone marrow lesions and collapse of subchondral bone (Figure 1(a-a1) and (b-b1), $n = 4$ per group) which has
been reported to be associated with the resultant pain behavior.\textsuperscript{45}

All of the rats that received 2 mg MIA knee injection exhibited asymmetric hindlimb weight bearings (WB) throughout the course of the study, confirming OA knee spontaneous pain development following MIA knee injection. Specifically, following MIA knee injection, animals displayed significant reduction of WB on the ipsilateral hind limb compared to their respective saline control with weight symmetry. The magnitudes of WB reduction were similar to previous reports\textsuperscript{25,26} and persisted during the entire five weeks after OA induction. In addition to pain on loading (WB), all animals injected with MIA developed consistent and significant ipsilateral mechanical allodynia to normally innocuous mechanical stimulation (brush and vF) and hyperalgesia to noxious mechanical stimulation (Pin), as well as hypersensitivity to heat and acetone (Figure 1(c)–(h)). These were evident by one week and persisted for the entire five weeks for which the MIA-injected animals were tested. Mechanical allodynia (vF) but not mechanical hyperalgesia or thermal stimulation was also observed on the contralateral hindpaw (Figure 1(d), (e) and (g)). These data show that MIA induces significant local (knee joint) and remote (hindpaw) sensitization. Conceivably, the mechanical and thermal stimulated hindpaw withdraw during tests can also facilitate knee local pain because of knee movement triggered by repeated stimulation at hindpaw plantar. These findings, together with previous observations by others,\textsuperscript{46} indicate that MIA-induced OA, in addition to direct unilateral knee damage, induces central sensitization that can also spread sensitization to the contralateral hindpaw.

**MIA-OA increases T-type $\text{Ca}^{2+}$ channel current in PSNs**

Abundant data support an important role of $\text{CaV}_{3.2}$ in generating pain states including various inflammatory and neuropathic pain models.\textsuperscript{20} We next focused on examining whether T-type $\text{Ca}^{2+}$ channel activity was altered in the MIA OA model, using electrophysiological recording of T-channel current ($I_{\text{Ca}}$) of PSNs dissociated from DRGs five weeks after MIA injection. LVA current was isolated by blocking HVA currents with specific toxins.\textsuperscript{39} We chose to record from small- to medium-size PSNs ($< 40 \mu m$ soma diameter) because these are likely nociceptors and have T-type currents under normal conditions.\textsuperscript{53,54} Since ATF3 immunostaining indicated neuronal damage in the majority PSNs in L3, L4, and L5 DRG at the late stage after 2 mg MIA injection, whole-cell patch-clamp was conducted on the randomly selected PSNs dissociated from L3, L4, and L5 DRG, individually ($n = 4$ for each L3, L4, and L5 DRG from four rats per group). To determine the expression of T-type currents, we set holding potentials ($V_h$) to $-90 mV$ and recorded currents during depolarizations to test potentials ($V_t$) of $-80$ to $+60 mV$ in $10 mV$ increments. The resulting inward currents showed a crossing pattern of T-type channels (Figure 3(a) and (b)). Neurons expressing LVA currents represented 44% (60 out of 137 cells recorded) of the total population in saline vs $47\%$ (60 out of 128 cells recorded) in MIA neurons. Application of 5 \mu M TTA-P2 inhibited $>90\%$ of the current, confirming that these were currents through the T-type channel. Current–voltage (I–V) relationships showed that average $I_{\text{Ca}}$ intensity was increased $2 \times$ fold for neurons from L3, L4, or L5 DRG of MIA animals compared to the saline-injected groups, across a wide range of test potentials ($-80$ to $+20 mV$) (Figure 3(c)–(f)). No significant
alteration on the voltage-dependent activation and steady-state inactivation properties was observed (Figure 3(g)–(h)). Together, the results suggest that T-type channel activity was significantly enhanced after MIA compared to the control group; and this effect, since the activation and inactivation kinetics were spared, was unlikely due to the change in T-channel biophysical properties but might be resulted from the increased CaV3.2 expression that can lead to enhanced channel activity.18,55

MIA-OA induces increased CaV3.2 expression in nociceptive pathways

We next examined and compared CaV3.2 protein expression in DRG and SDH between MIA- and saline-treated animals at the advanced stage (35 days) of MIA OA by IHC and immunobLOTS. In the control DRG, high CaV3.2 IR signals were preferably detected in small- and medium-sized PSNs co-stained with IB4 and CGRP (Figure 4(a) and (b)). High CaV3.2-IR was also detected in the IB4, CGRP, pCaMKII, and Tubb3 positive axonal fibers in SN (Figure 4(c), (e), (f), (g)), as well as IB4 (Figure 4(d)) and Tubb3 (Figure 4(h)) positive dermal nerve bundles of hindpaw glabrous skin. IHC patterns of CaV3.2-IR in SC, DRG, and SN were in agreement with previous reports.33,55,56 Quantitative comparison of DRG-CaV3.2 protein levels was performed by western blots. Since neuronal damages with enhanced PSN T-channel ICa density were evident in multiple segments of lumber DRG derived from MIA-treated animals, pooled L3-L5 DRG were used to prepare samples for immunoblots. Results showed that CaV3.2 protein levels in the pooled L3-L5 DRG were significantly increased in the MIA-OA group compared to control samples (Figure 4(i)). Since the DRG tissues harvested contained adjacent roots and spinal nerve attached, the increased CaV3.2 protein levels reflected increased CaV3.2 in both PSNs and their axons. IHC examination on lumbar SC cross-sections showed fairly symmetric CaV3.2-IR preferably in the neurons of ipsilateral and contralateral SDH of saline-treated animals (Figure 5(a-a1)), whereas the CaV3.2-IR of ipsilateral DH (Figure 5(b)) that showed microgliosis (Figure 5(c)) in MIA-treated rats was apparently increased compared to the contralateral site (Figure 5(a) and (a1)), and

Figure 2. IHC characterization of PSN damage and inflammation. (a-e) shows representative IHC images stained for ATF3 (red) and counterstained by Hoechst on DRG sections five weeks after saline (a) or 2 mg MIA injection (L3, b; L4, c; and L5, d), with bar chart (e) showing the quantitative comparison of the percentage of ATF3-positive neurons in L3 to L5 DRG between saline and MIA groups (n = 3 DRG per group). Values are ATF3-positive number of total determinations (neurons with visible nuclei); *** denotes p < 0.001, two tailed unpaired Student's t tests. (f–m) show representative IHC staining for GFAP and Iba-1 on lumbar SC and DRG sections. In comparison with controls that display symmetrically scattered distribution of GFAP-positive astrocytes (green) and Iba1-positive microglia (green) in the lumbar SDH (f, h), marked gliosis for both astrocytes and microglia are seen ipsilateral to MIA OA in the SDH (g, i), with asterisks in panel (i) indicating microgliosis in dorsal root ipsilateral to MIA injection. In the DRG, minimal staining is evident for Iba-1 and GFAP after saline knee injection (j, l), but shows abundant positive staining after MIA knee injection for Iba-1 (k) and GFAP (m). Microgliosis is also evidence in sciatic nerve (cf. panel n of control and panel o of MIA). Scale bar: 50 μm for all.
this was verified by quantification of CaV3.2 immunolabeled fluorescent densities (Figure 5(d) to (f)). Quantitative comparison of CaV3.2 protein levels by western blots verified /C24 2 fold higher of CaV3.2 in the ipsilateral DH than that of contralateral DH (Figure 5(g)). Together, these experiments demonstrate that MIA-OA induces increased CaV3.2 expression in nociceptive pathways including PSNs and their axons and DH neurons, which may have implications for promotion of chronic pain, and consequently, blocking CaV3.2 channels should attenuate the pain behavior.

SN injection of TTA-P2 attenuates mechanical hypersensitivity and WB asymmetry

To further investigate whether enhanced CaV3.2 in the PSNS after MIA knee injection contributed to pain behavior, we evaluated the effects of ipsilateral SSNI of TTA-P2, a potent and selective blocker of T-channels and antinociceptive agent, on mechanical allodynia and hyperalgesia, as well as WB asymmetry in MIA rats. In this experiment, TTA-P2 effects on neuropathic pain-like sensitization were evaluated at day 35 after MIA injection, an advanced stage of knee joint damage with established pain behavior. The vF and Pin testing thresholds as well as WB asymmetry at day 35 after MIA injection, before SSNI TTA-P2 were measured as the treatment baseline (n = 5 rats). Results showed that a single delivery of 100 µg TTA-P2 to PNS by SSNI induced fast analgesic effects, and the peak effects by vF, Pin, and WB tests were achieved 30 min post injection, displaying completely normalized innocuous mechanical allodynia, hyperalgesia aversion, and WB symmetry; and the effects reduced to treatment baseline levels 2 h post-administration, compared to saline injected group (Figure 6(a)–(c)). No abnormal
ambulation was noted for animals injected with TTA-P2 during the testing period. These data indicate that selective block of CaV3.2 channels in the PNS leads to alleviation of mechanical hypersensitivity and WB asymmetry, suggesting that CaV3.2 channels likely play a role in hypersensitivity, at least, in the advanced stage of MIA OA pain.

**Discussion**

In this study, the involvement of PSN-T-type Ca\(^{2+}\) channel dysfunction at the late stage of MIA knee OA pain was demonstrated by several experimental evidence: (1) PSN-T-type ICa is significantly enhanced in L3-L5 DRG ipsilateral to MIA-OA, (2) CaV3.2 expression is increased in spinal dorsal horn and PSNs and their axons, and (3) PNS block of CaV3.2 function alleviates hindpaw mechanical allodynia and hyperalgesia, as well as WB asymmetry in MIA animals. Thus, our findings provide evidence linking enhanced PSN-CaV3.2 channel activity to MIA-OA pain perception during the late stage. Whether dysfunctional PSN-CaV3.2 is involved in the early inflammatory stage of MIA OA is not examined by this study.

The CaV3.2 is the predominant isoform of the T-type Ca\(^{2+}\) channel family, consisted of CaV3.1, CaV3.2, and CaV3.3, found in PSNs. CaV3.2 channels that modulate the function of peripheral and central nociceptive pathways by influencing peripheral sensory perception, neuronal excitability, and SC synaptic plasticity and neurotransmitter release. Elevated expression and/or enhanced functionality of CaV3.2 channels have been well-defined, in overall, a range of painful conditions across a variety of animal models, including inflammatory pain, neuropathic pain, diabetic peripheral neuropathic pain, chemotherapy-induced peripheral neuropathy, and postsurgical pain model (i.e. paw incision). Activation of CaV3.2 channels following nerve damage in these models play critical roles in generating peripheral and central sensitization manifesting as pain hypersensitivity. An increased CaV3.2 activity that underlies the OA pain pathology is implicated;
Figure 5. Increased expression of CaV3.2 in DH of MIA OA pain rats. Representative IHC montage images of CaV3.2-IR (a, green) and merged image of CaV3.2 colabeled with IB4 (a1, red) show that CaV3.2 is symmetrically distributed in the bilateral SDH of saline-treated rat. CaV3.2-IR in DH and dorsal column regions is apparently increased (b), parallel with the increased Iba1-labeled microglia (c) in the ipsilateral (ipsi.) DH of MIA-treated rat. White dashed lines outline the approximate DH and SDH with white matter pseudocolored in blue. Scale bar: 100 μm for all. DH CaV3.2 immunolabeled fluorescent densities of saline (a) and MIA (b) were inverted, the upper and lower threshold optical densities of CaV3.2 signals adjusted to encompass and match the IR that appears in red (d) and (e), respectively; and quantified as described in Method. The rectangles (d and e) positioned over laminae territory throughout the mediolateral axis on the contra. and ipsi. DHs. The integrated density (product of area and density) calculated, and fold change (ipsi./contra.) summarized in panel (f). Quantitative comparison of CaV3.2 protein levels in DH between ipsilateral and contralateral sites was performed by Western blot. The images (g) and scattered dot plots with medians in the right of (g) summarize of the grouped data; * denote p < 0.05 by two-tailed unpaired Student’s t test.
Therefore, conceivably, the inflammatory responses and sensory neuron damage may also play pathological roles for upregulation of CaV3.2 in the context of MIA OA model since the function and expression of Cav3.2 are modulated by a variety of inflammatory and nerve injury mediators.20,57,69 For example, increased nerve growth factor and tumor necrosis factor-α are common pathological mediators in both neuropathic pain and OA pain, and both are known determinants of regulating T-type Ca2+ channels.10,20,51,69 These processes may cause peripheral and central sensitization and promote the persistence of neuropathic-like pain in MIA OA model.70

The decrease in pain sensation after peripheral injection of TTA-P2 adds further evidence for involvement of peripheral CaV3.2 activation in MIA OA pain. Previous studies have shown that acute anti-nociception to mechanical stimulation after SN perineural, intrathecal (i.t), or intraperitoneal (i.p) application of TTA-P2 is an effective approach in addressing enhanced CaV3.2 responses in animal models of both inflammatory and neuropathic pain, with the additional advantage that applied TTA-P2 exerts antinociceptive effects without motor impairment.40,53,59 T-type CaV3.2 channels are abundantly expressed in PSN somata and transported to peripheral and central axons where CaV3.2 contributes to pain perception, neuronal excitability, and spinal synaptic plasticity. Since CaV3.2 is also expressed in SC neurons, it is unclear whether peripheral or central block of CaV3.2 is best for analgesic efficacy. Our success in producing analgesia by sciatic injection of TTA-P2 suggests that a peripheral site of CaV3.2 channel action is involved in pain generation. Since our findings showed that elevated expression and function of CaV3.2 channels are found in PSNs at multiple lumbar segmental levels after MIA injection into the knee, TTA-P2 directly into the large nerve trunks of the SN could act on axonal CaV3.2 channels directly at the site of injection, or may spread to more central and peripheral sites of action by bulk flow and diffusion longitudinally within the sciatic and associated spinal nerves, or by axonal transport. Indeed, the direct application of drug to the SN can lead to changes in the properties of DRG neurons.43,71 It is likely that observed TTA-P2 analgesic effect is predominantly due to inhibition on T-type channels, although we cannot rule out the possibility of some effects on alternative molecular targets. Additionally, SN at the midthigh are composed of axonal fibers from sensory, motor, and sympathetic neurons that may also express T-channels 72,73; thus, the analgesic effect may be partially resulted from T-channel inhibition in those fibers that also play roles in generation of pain behavior.74,75

Figure 6. Reversal of mechanical pain behavior and weight-bearing asymmetry by sciatic nerve application of TTA-P2. Scatter and line plots show time courses for the group averages (n = 5) of sensitivity to von Frey (a) and Pin (b), as well as weight-bearing asymmetry (c, n = 4) following ipsilateral subperineural sciatic nerve injection (SSNI) of TTA-P2 (100 μg, 100 μl) or saline (100 μl), determined at day 35 after MIA-OA induction. Right panels show averaged area under the curve (AUC) calculated for each individual for 1 h period (15 min interval) following injection for von Frey, Pin, and weight-bearing tests, respectively. Behavior tests at 35 days before injection were used as the treatment baseline values for AUC calculation. ***p < 0.001 for comparison to treatment BL and \( p< 0.05, \* \* \* p< 0.01, \* \* \* p< 0.001 \) for comparison between groups after treatment, respectively (repeated measures two-way ANOVA and post-hoc analysis with Bonferroni test for von Frey and weight bearing, and nonparametric analyses by Friedman’s test with Dunn’s post hoc for Pin. *\( p< 0.05 \) and ***\( p< 0.001 \) for AUC comparison between groups (two-tailed unpaired Student’s t tests).
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant from the Department of Veterans Affairs Rehabilitation Research and Development I01RX001940 (to QH), a National Institutes of Health grants R61NS116203 (to HY and QH), and a MCW Development I01RX001940 (to QH), a National Institutes of Department of Veterans Affairs Rehabilitation Research and article: This research was supported by a grant from the article.

The author(s) declared receipt of the following financial sup-

References
1. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet 2005; 365: 965–973.
2. Schmidt MM, Dringen R. Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes. Front Neuroenergetics 2009; 1: 1.
3. Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheumat 2014; 44: 145–154.
4. Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, Im H-J. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene 2013; 527: 440–447.
5. Kuyinu EL, Narayanan G, Nair LS, Laurencin CT. Animal models of osteoarthritis: classification, update, and measurement of outcomes. J Orthop Surg Res 2016; 11: 19.
6. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol 2013; 9: 654–664.
7. Thakur M, Dickenson AH, Baron R. Osteoarthritis pain: nociceptive or neuropathic? Nat Rev Rheumatol 2014; 10: 374–380.
8. Zhu S, Zhu J, Zhen G, Hu Y, An S, Li Y, Zheng Q, Chen Z, Yang Y, Wan M, Skolaskey RL, Cao Y, Wu T, Gao B, Yang M, Gao M, Kuliwaba J, Ni S, Wang L, Wu C, Findlay D, Eltzschig HK, Ouyang HW, Crane J, Zhou F-Q, Guan Y, Dong X, Cao X. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Invest 2019; 129: 1076–1093.
9. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartil 2013; 21: 1145–1153.
10. Miller RE, Tran PB, Obeidat AM, Raghu P, Ishihara S, Miller RJ, Malfait A-M. The role of peripheral nociceptive neurons in the pathophysiology of osteoarthritis pain. Curr Osteoporos Rep 2015; 13: 318–326.
11. McDougall JJ, Bray RC, Sharkey KA. Morphological and immunohistochemical examination of nerves in normal and injured collateral ligaments of rat, rabbit, and human knee joints. Anat Rec 1997; 248: 29–39.
12. Hildebrand C, Oqvist G, Brux L, Tuisku F. Anatomy of the rat knee joint and fibre composition of a major articular nerve. Anat Rec 1991; 229: 545–555.
13. Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol 2019; 15: 355–363.
14. Lockwood SM, Lopes DM, McMahon SB, Dickenson AH. Characterisation of peripheral and central components of the rat monooiodoacetate model of osteoarthritis. Osteoarthritis Cartil 2019; 27: 712–722.
15. Fingleton C, Smart K, Moloney N, Fullen BM, Doody C. Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartil 2015; 23: 1043–1056.
16. Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, Graven-Nielsen T. Sensitization in patients with painful knee osteoarthritis. Pain 2010; 149: 573–581.
17. Eitner A, Hofmann GO, Schauble HG. Mechanisms of osteoarthritic pain. Studies in humans and experimental models. Front Mol Neurosci 2017; 10: 349.
18. Todorovic SM, Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol 2011; 163: 484–495.
19. François A, Schütter N, Laffray S, Sanguesa J, Pizzoccaro A, Dibel S, Mantilleri A, Nargeot J, Noël J, Wood JN, Moqrich A, Pongs O, Bourinet E. The low-threshold calcium channel Cav3.2 determines low-threshold mechanoreceptor function. Cell Rep 2015; 10: 370–382.
20. Bourinet E, Francois A, Laffray S. T-type calcium channels in neuropathic pain. Pain 2016; 157: S15–22.
21. Shao Y, Alicknavitch M, Farach-Carson MC. Expression of voltage sensitive calcium channel (VSCC) L-type Cav1.2 (alpha1C) and T-type Cav3.2 (alpha1H) subunits during mouse bone development. Dev Dyn 2005; 234: 54–62.
22. Snrivasan PP, Parajuli A, Price C, Wang L, Duncan RL, Kim-Safran CB. Inhibition of T-type voltage sensitive calcium channel reduces load-induced OA in mice and suppresses the catabolic effect of bone mechanical stress on chondrocytes. PLoS One 2015; 10: e0127290.
23. Jarvis MF, Scott VE, McGaraughty S, Chu KL, Xu J, Niforatos W, Milicic I, Joshi S, Zhang Q, Xia Z. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem Pharmacol 2014; 89: 536–544.
24. Felson DT. Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther 2009; 11: 203.
25. Thakur M, Rahman W, Hobbs C, Dickenson AH, Bennett DL. Characterisation of a peripheral neuropathic component of the rat monooiodoacetate model of osteoarthritis. PLoS One 2012; 7: e33730.
26. Im H-J, Kim J-S, Li X, Kotwal N, Sumner DR, van Wijnen AJ, Davis FJ, Yan D, Levine B, Henry JL, Desevbé J, Kroin JS. Alteration of sensory neurons and
spinal response to an experimental osteoarthritis pain model. *Arthritis Rheum* 2010; 62: 2995–3005.

27. Fischer G, Kostic S, Nakai H, Park F, Sapunar D, Yu H, Hogan Q. Direct injection into the dorsal root ganglion: technical, behavioral, and histological observations. *J Neurosci Methods* 2011; 199: 43–55.

28. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, Kilgore KS. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. *Osteoarthritis Cartilage* 2003; 11: 821–830.

29. Wu HE, Gemes G, Zoga V, Kawano T, Hogan QH. Learned avoidance from noxious mechanical simulation but not threshold Semmes Weinstein filament stimulation after nerve injury in rats. *J Pain* 2010; 11: 280–286.

30. Mapp PI, Sagar DR, Ashraf S, Burston JJ, Suri S, Chapman V, Walsh DA. Differences in structural and pain phenotypes in the sodium monoiodoacetate and meniscal transection models of osteoarthritis. *Osteoarthritis Cartilage* 2013; 21: 1336–1345.

31. Haywood AR, Hathway GJ, Chapman V. Differential contributions of peripheral and central mechanisms to pain in a rodent model of osteoarthritis. *Sci Rep* 2018; 8: 7122.

32. Yu H, Fischer G, Jia G, Reiser J, Park F, Hogan QH. Lentiviral gene transfer into the dorsal root ganglion of adult rats. *Mol Pain* 2011; 7: 63.

33. Jacus MO, Ubele VN, Renger JJ, Todorovic SM. Presynaptic Cav3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. *J Neurosci* 2012; 32: 9374–9382.

34. Yu H, Fischer G, Ferhatovic L, Fan F, Light AR, Weirath D, Sapunar D, Nakai H, Park F, Hogan QH. Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. *PLoS One* 2013; 8: e61266.

35. Corder G, Siegel A, Intondi AB, Zhang X, Zadina JE, Taylor BK. A novel method to quantify histochemical changes throughout the mediolateral axis of the substantia gelatinosa after spared nerve injury: characterization with TRPV1 and substance P. *J Pain* 2010; 11: 388–398.

36. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis GW, Salo P, McDougall JJ, Prescott SA, Matyas JR, Taylor BK. A novel method to quantify histochemical changes throughout the mediolateral axis of the substantia gelatinosa after spared nerve injury: characterization with TRPV1 and substance P. *J Pain* 2010; 11: 388–398.

37. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis GW, Salo P, McDougall JJ, Prescott SA, Matyas JR, Taylor BK. A novel method to quantify histochemical changes throughout the mediolateral axis of the substantia gelatinosa after spared nerve injury: characterization with TRPV1 and substance P. *J Pain* 2010; 11: 388–398.

38. Xiang H, Xu H, Fan F, Shin SM, Hogan QH, Yu H. Glial fibrillary acidic protein promoter determines transgene expression in satellite glial cells following intraganglionic adeno-associated virus delivery in adult rats. *J Neurosci Res* 2018; 93: 436–448.

39. Pan B, Guo Y, Wu H-E, Park J, Trinh VN, Luo ZD, Hogan QH. Thrombospondin-4 diversely regulates voltage-gated Ca2+ channel subtypes in sensory neurons after nerve injury. *Pain* 2016; 157: 2068–2080.

40. Choe W, Messinger RB, Leach E, Ecke V-S, Obradovic A, Salajegheh R, Jevtovic-Todorovic V, Todorovic SM. TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinoceptive agent. *Mol Pharmacol* 2011; 80: 900–910.

41. Moayeri N, Groen GJ. Differences in quantitative architecture of sciatic nerve may explain differences in potential vulnerability to nerve injury, onset time, and minimum effective anesthetic volume. *Anesthesiology* 2009; 111: 1128–1134.

42. Estebe JP, Myers RR. Amitriptyline neurotoxicity: dose-related pathology after topical application to rat sciatic nerve. *Anesthesiology* 2004; 100: 1519–1525.

43. Flinspach M, Xu Q, Piekarz AD, Fellows R, Hagan R, Gibbs A, Liu Y, Neff RA, Freedman J, Eckert WA, Zhou M, Bonesteel R, Pennington MW, Eddinger KA, Yakshe TL, Hunter M, Swanson RV, Wickenden AD. Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. *Sci Rep* 2017; 7: 39662.

44. Ferreira-Gomes J, Adae S, Sarkander J, Castro-Lopes JM. Phenotypic alterations of neurons that innervate osteoarthritic joints in rats. *Arthritis Rheum* 2010; 62: 3677–3685.

45. Nwosu LN, Mapp PI, Chapman V, Walsh DA. Relationship between structural pathology and pain behaviour in a model of osteoarthritis (OA). *Osteoarthritis Cartilage* 2016; 24: 1910–1917.

46. Havelin J, Imbert I, Cormier J, Allen J, Porreca F, King T. Central sensitization and neuropathic features of ongoing pain in a rat model of advanced osteoarthritis. *J Pain* 2016; 17: 374–382.

47. Braz JM, Basbaum AI. Differential ATF3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli. *Pain* 2010; 150: 290–301.

48. Averill S, Michael GJ, Shortland PJ, Leavesley RC, King VR, Bradbury EJ, McMahon SB, Priestley JV. NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury. *Eur J Neurosci* 2004; 19: 1437–1445.

49. Mousseau M, Burma NE, Lee KY, Leduc-Pessah H, Kwok CHT, Reid AR, O’Brien M, Sagalajev B, Stratton JA, Patrick N, Stemkowski PL, Biernaskie J, Zamponi KW, Arai G, Toyone T, Aoki Y, Kubo T, Takahashi K, Ohtori S. Pain-related sensory innervation occurs in dorsal root ganglion cells in response to peripheral nerve injury. *Eur J Neurosci* 2004; 19: 1437–1445.

50. Sagar DR, Burston JJ, Hathway GJ, Woodhams SG, Pearson RG, Bennett AJ, Kendall DA, Scammell BE, Chapman V. The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain. *Mol Pain* 2011; 7: 1744-8069-7-88.

51. Orita S, Ishikawa T, Miyagi M, Ochiai N, Inoue G, Eguchi Y, Kamoda H, Arai G, Toyone T, Aoki Y, Kubo T, Takahashi K, Ohtori S. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. *BMC Musculoskelet Disord* 2011; 12: 134.
The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a novel subpopulation of peripheral nociceptors. *J Neurosci* 2005; 25: 8766–8775.

Li Y, Tatsui CE, Rhines LD, North RY, Harrison DS, Rose KE, Lunardi N, Boscolo A, Dong X, Erisir A, Battista A, Fu E0127572.

Ca2+ channel-dependent sensitization of a novel subpopulation of peripheral nociceptors. *J Neurosci* 2013; 250: 263–274.

Watanabe M, Ueda T, Shibata Y, Kumamoto N, Shimada S, Ugawa S. Expression and regulation of Cav3.2 T-Type calcium channels during inflammatory hyperalgesia in mouse dorsal root ganglion neurons. *PLoS One* 2015; 10: e0127572.

58. Marger F, Gelot A, Alloui A, Matricone J, Ferrer JFS, Barrière C, Pizzoccaro A, Muller E, Nargeot J, Snutch TP, Eschalier A, Bourinet E, Ardid D. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. *Proc Natl Acad Sci USA* 2011; 108: 11268–11273.

59. Chen W, Chi Y-N, Kang X-J, Liu Q-Y, Zhang H-L, Li Z-H, Zhao Z-F, Yang Y, Su L, Cai J, Liao F-F, Yi M, Wan Y, Liu F-Y. Accumulation of Cav3.2 T-type calcium channels in the uninjured sural nerve contributes to neuropathic pain in rats with spared nerve injury. *Front Mol Neurosci* 2018; 11: 24.

60. Kang X-J, Chi Y-N, Chen W, Liu F-Y, Cui S, Liao F-F, Cai J, Wan Y. Increased expression of Cav3.2 T-type calcium channels in damaged DRG neurons contributes to neuropathic pain in rats with spared nerve injury. *Mol Pain* 2018; 14: 1744806918765808.

61. Ayoola C, Hwang SM, Hong SJ, Rose KE, Boyd C, Bozic N, Park J-Y, Osuru HP, DiGruccio MR, Covey DF, Jevtovic-Todorovic V, Todorovic SM. Inhibition of Cav3.2 T-type calcium channels in peripheral sensory neurons contributes to analgesic properties of epipregnanolone. *Psychopharmacology (Berl)* 2014; 231: 3503–3515.

62. Todorovic SM, Jevtovic-Todorovic V. Targeting of Cav3.2 T-type calcium channels in peripheral sensory neurons for the treatment of painful diabetic neuropathy. *Pflugers Arch* 2014; 466: 701–706.

63. Latham JR, Pathirathna S, Jagodic MM, Choe WJ, Levin ME, Nelson MT, Lee WY, Krishnan K, Covey DF, Todorovic SM, Jevtovic-Todorovic V. Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice. *Diabetes* 2009; 58: 2656–2665.

64. Tomita S, Sekiguchi F, Deguchi T, Miyazaki T, Ikeda Y, Tsubota M, Yoshida S, Nguyen HD, Okada T, Toyooka N, Kawabata A. Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice. *Toxicol* 2019; 413: 33–39.

65. Wu Q, Henry JL. Changes in abeta non-nociceptive primary sensory neurons in a rat model of osteoarthritis pain. *Mol Pain* 2010; 6: 37.

66. Miller RE, Kim YS, Tran PB, Ishihara S, Dong X, Miller RJ, Malfait A-M. Visualization of peripheral neuron sensitization in a surgical mouse model of osteoarthritis by in vivo calcium imaging. *Arthritis Rheumatol* 2018; 70: 88–97.

67. O’Neill TW, Felson DT. Mechanisms of osteoarthritis (OA) pain. *Curr Osteoporos Rep* 2018; 16: 611–616.

68. Feng X-J, Ma L-X, Jiao C, Kuang H-X, Zhou Y-Y, Cheng X-E, Zhu M-Y, Zhang D-Y, Jiang C-Y, Liu T. Nerve injury elevates functional Cav3.2 channels in superficial spinal dorsal horn. *Mol Pain* 2019; 15: 1744806919836569.

69. Sekiguchi F, Tsubota M, Kawabata A. Involvement of voltage-gated calcium channels in inflammation and inflammatory pain. *Biol Pharm Bull* 2010; 33: 983–993.

70. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. *Nat Med* 2010; 16: 1267–1276.

71. DiStefano PS, Friedman B, Radziejewski C, Alexander C, Boland P, Schick CM, Lindsay RM, Wiegand SJ. The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. *Neuron* 1992; 8: 983–993.

72. Kisiswa L, Erice C, Ferron L, Wyatt S, Osorio C, Dolphin AC, et al. T-type Ca2+ channels are required for enhanced sympathetic axon growth by TNFalpha reverse signalling. *Open Biol* 2017; 7: 160288.

73. Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. *J Neurosci* 1998; 18: 6319–6330.

74. Schlereth T, Birklein F. The sympathetic nervous system and pain. *Neuromolecular Med* 2008; 10: 141–147.

75. Boadas-Vaello P, Castany S, Homs J, Alvarez-Perez B, Deulofeu M, Verdú E. Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets. *Spinal Cord* 2016; 54: 330–340.